Key result
Ribavirin clears persistent hepatitis E in a heart transplant recipient after immunosuppression reduction fails.
Why the study?
Hepatitis E virus infection poses a significant public health burden in immunosuppressed individuals.
Does reduction of immunosuppressants or addition of ribavirin clear HEV infection in a heart transplant recipient?
Case Report (n=1)
Does reduction of immunosuppressants or addition of ribavirin clear HEV infection in a heart transplant recipient?
Ribavirin therapy, rather than just reducing immunosuppression, was required to successfully clear Hepatitis E virus infection in a heart transplant recipient.
HEV may prolong liver dysfunction in heart transplant recipients with weak IgG response; leaves open optimal immunosuppression adjustment.
Hepatitis E virus (HEV) infection poses a significant public health burden in immunosuppressed individuals. Here, we report a 41-year-old male patient with a history of orthotopic heart transplantation, who develop HEV genotype 4 (subtype 4d) infection one-and-a-half-year post-transplantation. The patient exhibits a very weak anti-HEV IgG response. Abnormal liver function parameters persist for one month without evidence of clinical improvement. Therefore, the immunosuppressant dosage is halved to promote effective antiviral response. The anti-HEV IgG response gradually increases; however, abnormal liver function parameters persist into the second month, and HEV infection fails to clear. The patient is administered ribavirin at a dose of 600 mg/d, and by the third month, the viral load significantly decreases. By the fourth month, HEV infection is successfully cleared, liver function parameters returned to normal, and no viral reactivation is observed through the eighth month. This work highlights therapeutic approaches for managing HEV infection in solid organ transplantation (SOT) recipients.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a case report in Hepatitis E virus (HEV) infection (n=1). Immunosuppressant reduction and ribavirin was evaluated on Viral clearance and liver function normalization. Halving immunosuppressant dosage failed to clear Hepatitis E virus infection in a heart transplant recipient, whereas subsequent administration of ribavirin 600 mg/d successfully cleared the virus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: